Bntx stocks.

Pfizer ( PFE -1.46%) stock was down 3.5%. Shares of BioNTech ( BNTX -2.08%) and Moderna ( MRNA -1.55%) were sinking 7.6% and 8.2%, respectively. However, Pfizer and BioNTech actually had good news ...

Bntx stocks. Things To Know About Bntx stocks.

Jan 25, 2023 · Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), like BioNTech SE (NASDAQ:BNTX), and AbbVie Inc. (NYSE:ABBV), is a highly popular biotech stock today, as evidenced by the number of hedge funds ... Nov 4, 2021 · Shares of BioNTech (BNTX-1.01%) were 9.1% lower as of 11:51 a.m. EDT on Thursday. The German biotech didn't report any news, so why did its stock slide? ... But stocks that share common ... Get BioNTech SE (BNTX.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsWelcome to our investor page. Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid …Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next 30-90 days. Recent stocks from this report have soared up to +178.7% in 3 months - this month ...

Interactive Chart for BioNTech SE (BNTX), analyze all the data with a huge range of indicators.BNTX Earnings Date and Information. BioNTech last posted its earnings data on November 6th, 2023. The reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $1.26. The firm had revenue of $895.30 million for the quarter, compared to analyst estimates of $850.50 million.BioNTech SE BNTX has reported Q3 revenues of €895.3 million ($974.49 million), sharply down from €3.461 billion a year ago. Analysts estimated $1.06 billion in sales. For the nine months ...

Discover historical prices for BNTX stock on Yahoo Finance. View daily, weekly or monthly format back to when BioNTech SE stock was issued.

16 Oct 2023 ... Topline. Stocks of Pfizer and other Covid vaccine makers like BioNTech and Moderna fell in premarket trading Monday after the company slashed ...Track Better Therapeutics Inc (BTTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsNov 5, 2021 · Shares of BioNTech ( BNTX -0.31%) were plunging 19.8% as of 11:12 a.m. EDT on Friday. The steep decline came after Pfizer ( PFE 0.50%) announced positive results from a late-stage study of its ... Jun 18, 2023 · BNTX Stock Assessment. Per Seeking Alpha, BioNTech's stock assessment reveals a mixed bag of results. In terms of valuation, the company is rated "A+" with forward-looking non-GAAP P/E at 20.76 ...

Over the past 3 months, 12 analysts have published their opinion on BioNTech (NASDAQ:BNTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a ...

BioNTech SE (ADR) share price in real-time (A2PSR2 / US09075V1026), charts and ... Frankfurt Stock Exchange · Securities · Trading · Glossary · Publications ...

3. BioNTech. Per its coronavirus vaccine collaboration with Pfizer, BioNTech ( BNTX 1.40%) is the only company on this list that's currently earning revenue as a result of its sales of mRNA ...3 days ago ... JPMorgan downgrades BioNTech (BNTX) due to uncertain outlook for COVID-19 vaccine, hurting company's shares in the pre-market.The public float for BNTX is 237.70M, and currently, short sellers hold a 1.37% ratio of that floaft. The average trading volume of BNTX on November 23, 2023 was 669.58K shares. BNTX’s Market Performance. BNTX stock saw an increase of -2.73% in the past week, with a monthly gain of 2.25% and a quarterly increase of -17.72%.BNTX Stock: Mixed Performance and Challenges in Profitability and Growth. On November 6, 2023, BNTX stock showed mixed performance based on the available data. BNTX is a company in the Health Technology sector, specifically in the Biotechnology industry. With a market cap of $23.2 billion, BNTX is a significant player in the biotech field.Dec 1, 2023 · BNTX Earnings Date and Information. BioNTech last issued its quarterly earnings results on November 6th, 2023. The reported $0.67 earnings per share for the quarter, topping the consensus estimate of ($0.59) by $1.26. The business earned $895.30 million during the quarter, compared to analyst estimates of $850.50 million.

US09075V1026. BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2 ... Stock Price Forecast ... The 16 analysts offering 12-month price forecasts for BioNTech SE have a median target of 124.69, with a high estimate of 264.82 and a ...BNTX stock analysts projected a per-share loss of 30 cents. BioNTech blamed write-offs to partner Pfizer for the profit and sales hits. On today's stock market, BNTX stock toppled 7.5% to 98.50.Dec 1, 2023 · It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ... The share price of BioNTech SE (BNTX) now. What analysts predict: $142.42. 52-week High/Low: $188.99 / $88. 50/200 Day Moving Average: $101.74 / $113.19. This figure corresponds to the Average Price over the previous 50/200 days. For BioNTech stocks, the 50-day moving average is the resistance level today.

BNTX stock didn’t just start moving in 2020 with the Covid-19 vaccine. It’s been on a growth path since it was first listed on the Nasdaq in the fall of 2019.

You can buy and sell BioNTech SE (BNTX) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. Other Robinhood Financial fees may apply, check rbnhd.co/fees for details.You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.What is BioNTech SE (BNTX)'s stock price today? The current price of BNTX is $99.39. The 52 week high of BNTX is $188.99 and 52 week low is $88.00. When is next earnings date of BioNTech SE (BNTX)?Novavax, Inc. stock has been facing a downward spiral, but there may be a short-term trading opportunity if FDA approval for its COVID-19 vaccine is positive. The high level of short interest in ...Mar 27, 2023 · That comes out to about $9.97 and $4.61 billion, respectively. Both metrics topped BNTX stock analysts' forecasts, though earnings fell 24% and sales tumbled 23%. Apr 20, 2023 · Nevertheless, contrarians might want to consider picking up BNTX. First, it sits among the blue-chip stocks with value based on key financial ratios. First, BNTX trades at a trailing multiple of 3 ...

8.04. Market cap. 23.49bn USD. EPS (TTM) 12.30. USD. Data delayed at least 15 minutes, as of Nov 24 2023 18:00 GMT. Latest BioNTech SE (BNTX:NSQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.

Dec 1, 2023 · BNTX Earnings Date and Information. BioNTech last issued its quarterly earnings results on November 6th, 2023. The reported $0.67 earnings per share for the quarter, topping the consensus estimate of ($0.59) by $1.26. The business earned $895.30 million during the quarter, compared to analyst estimates of $850.50 million.

The analyst Jessica Fye also trims her price target on BNTX to $99 from $106 per share, arguing that the sinking estimations for the company's COVID-19 vaccine business have hurt the stock "and ...A monster revenue miss was the big reason for the widespread investor sell-off in BioNTech ( BNTX 0.89%) stock on Monday. As of late-session trading that day, the once-hot biotech's share price ...The stock of BioNTech SE ADR (BNTX) has gone down by -2.01% for the week, with a 3.63% rise in the past month and a -20.46% drop in the past quarter. The volatility ratio for the week is 3.45%, and the volatility levels for the past 30 days are 3.21% for BNTX. The simple moving […]US09075V1026. BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2 ...You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Track Better Therapeutics Inc (BTTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsMar 2, 2023 · Biopharmaceutical New Technologies or BioNTech ( NASDAQ: BNTX) is a large ($31 billion market cap) immunotherapy company. They are developing cancer product candidates (Figure 1) but known mostly ... CEO. Website. 2008. 5,700. Ugur Sahin. https://www.biontech.de. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is …

German immunotherapy developer BioNTech (BNTX) raised $150 million in a US IPO that values the company at $3.4 billion. Despite pricing below its last round, BioNTech is the third-largest biotech ...Nov 29, 2023 · See the latest BioNTech SE ADR stock price (BNTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. The Biontech Se Sponsored Adr stock price fell by -1.01% on the last day (Friday, 1st Dec 2023) from $100.41 to $99.40. During the last trading day the stock fluctuated 5.12% from a day low at $94.78 to a day high of $99.63. The price has been going up and down for this period, and there has been a -0.3% loss for the last 2 weeks.Whatever the trade. ** U.S.-listed shares of German vaccine maker BioNTech NASDAQ:BNTX, NASDAQ:BNTX down 3.2% at $97.16 premarket** J.P.Morgan cuts rating of the stock to "underweight" from "neutral"** Brokerage expects BNTX's COVID-19 vaccine business to remain profitable but says revenue from it may not be able to f….Instagram:https://instagram. diversified reita.i.t.palladium vs platinum priceswks stock forecast Jan 20, 2022 · BioNTech stock (NASDAQ: BNTX), a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, declined by almost 31% over the last month, considerably underperforming the S&P 500 ... Company Profile. Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its ... whats inside the las vegas spherefutures course About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.Buy BioNTech Stock. BioNTech SE (BNTX) is a publicly traded biotechnology business based in the US. It opened the day at $99.94 after a previous close of $98.83. During the day the price has varied from a low of $98.66 to a high of $99.94. The latest price was $99.18 (25 minute delay). solid state battery company BNTX Stock Analysis: Negative Earnings Growth and Potential Risks in the Biotechnology Industry. On August 28, 2023, BNTX stock opened at $119.67 and experienced a range of $119.48 to $122.17 throughout the day. The trading volume for the day was 25,809, significantly lower than the average volume of 750,081 over the past three months.BNTX Description — BioNTech SE. BioNTech develops immunotherapies for cancer and other diseases. Co.'s immunotherapy product candidates span the following four drug classes: messenger ribonucleic acid (mRNA) therapeutics, in which it is utilizing mRNA to deliver genetic information to cells; cell therapies, in which it is developing a range of cell …